Edesa Biotech Wins FDA Clearance for Phase 2 Vitiligo Study
FDA cleared Edesa Biotech's IND application for a Phase 2 vitiligo study of EB06, enabling expansion to U.S. sites. U.S. enrollment is expected to begin in the first quarter of 2027; topline results are anticipated in the fourth quarter of 2027. Disclaimer: This news brief was created by Public Technologies (PUBT) usin